In this issue:
CRC screening with flexible sigmoidoscopy
Regorafenib benefits treatment-refractory mCRC
Treatments and outcomes by age groups in mCRC
Adjuvant bevacizumab: no benefit in resected CRC
Aflibercept + FOLFIRI: survival benefits in mCRC
Continuing bevacizumab after first progression
Assessing S-1 as an option in mCRC
Cetuximab beneficial in KRAS wt mCRC . . .
. . . and in KRAS G13Dmutant tumours
Limit panitumumab to KRAS wt mCRC?
Please login below to download this issue (PDF)